Table 5.

Analysis of variance of results of dose proportionality for GS-9851, GS-566500, and GS-331007 (all capsule formulations)

Parameter	Comparison	ANOVA result for drug
		GS-9851		GS-566500		GS-331007
		Ratio	90% CI	Ratio	90% CI	Ratio	90% CI
AUC0–∞ (h · ng/ml)	25 mg/100 mg					0.91	0.68, 1.22
	50 mg/100 mg					0.92	0.70, 1.21
	200 mg/100 mg			0.91	0.48, 1.76	0.84	0.58, 1.22
	400 mg/100 mg			0.52	0.29, 0.94	0.74	0.56, 0.98
	800 mg/100 mg			0.64	0.36, 1.14	0.50	0.37, 0.67
AUC0–t (h · ng/ml)	25 mg/100 mg	0.52	0.24, 1.11			0.85	0.63, 1.15
	50 mg/100 mg	1.00	0.56, 1.79	1.01	0.51, 1.98	0.89	0.68, 1.18
	200 mg/100 mg	0.48	0.27, 0.85	0.40	0.22, 0.75	0.69	0.53, 0.91
	400 mg/100 mg	0.64	0.36, 1.15	0.70	0.38, 1.29	0.73	0.55, 0.98
	800 mg/100 mg	1.01	0.57, 1.77	0.89	0.49, 1.61	0.51	0.39, 0.67
Cmax (ng/ml)	25 mg/100 mg	1.06	0.61, 1.84			1.08	0.85, 1.38
	50 mg/100 mg	1.19	0.72, 1.98	1.26	0.74, 2.12	0.99	0.79, 1.24
	200 mg/100 mg	0.76	0.46, 1.26	0.45	0.28, 0.71	0.53	0.42, 0.66
	400 mg/100 mg	0.58	0.34, 0.97	0.45	0.28, 0.72	0.49	0.39, 0.62
	800 mg/100 mg	0.99	0.59, 1.64	0.53	0.33, 0.84	0.32	0.26, 0.40